TY - JOUR T1 - Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors JF - medRxiv DO - 10.1101/2019.12.24.19015750 SP - 2019.12.24.19015750 AU - Jake P. Mann AU - Paul Carter AU - Matthew J. Armstrong AU - Hesham K Abdelaziz AU - Hardeep Uppal AU - Billal Patel AU - Suresh Chandran AU - Ranjit More AU - Philip N. Newsome AU - Rahul Potluri Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/30/2019.12.24.19015750.abstract N2 - Background Non-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the metabolic syndrome. Though NAFLD may progress to end-stage liver disease, the top cause of mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-related mortality in NAFLD derives from specialist liver centres. We aimed to assess mortality in NAFLD when adjusting for CVD in a ‘real world’ cohort of inpatients.Methods Retrospective study of hospitalised patients with 14-years follow-up. NAFL (non-alcoholi c fatty liver), non-alcoholic steatohepatitis (NASH), and NAFLD-cirrhosis groups were defined by ICD-10 codes using ACALM methodology. Cases were age-/sex-matched 1:10 with non-NAFLD hospitalised patients from the ACALM registry. All-cause mortality was compared between groups using cox regression adjusted for CVD and metabolic syndrome risk factors.Results We identified 1238 patients with NAFL, 105 with NASH and 1235 with NAFLD-cirrhosis. There was an increasing burden of cardiovascular disease with progression from NAFL to NASH to cirrhosis. After adjustment for demographics, metabolic syndrome components and cardiovascular disease, patients with NAFL, NASH, and cirrhosis all had increased all-cause mortality (HR 1.3 (CI 1.1-1.5), HR 1.5 (CI 1.0-2.3) and HR 3.5 (CI 3.3-3.9), respectively). Hepatic decompensation (NAFL HR 8.0 (CI 6.1-10.4), NASH HR 6.5 (2.7-15.4) and cirrhosis HR 85.8 (CI 72-104)), and hepatocellular carcinoma were increased in all NAFLD groups.Conclusion There is a high burden of cardiovascular disease in NAFLD-cirrhosis patients. From a large “real-life” non-specialist registry of hospitalized patients, NAFLD patients have increased overall mortality and rate of liver-related complications compared to controls after adjusting for cardiovascular disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z, https://wellcome.ac.uk).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll summary statistics available at requestACALMAlgorithm for Comorbidities, Associations, Length of stay and MortalityCVcardiovascularHRhazard ratioICD-10International Classification of Disease, 10th editionNAFLDnon-alcoholic fatty liver (disease)NASHnon-alcoholi c steatohepatitis ER -